tbuckley/cabot-search huggingface dataset:
ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer
Authors: K. Lee, S. Han, H. Min, D. Oh, S. Lee, D. Kim, Y. Kim, T. Kim, D. Heo, Y. Bang
Journal: Journal of Clinical Oncology (2007)

7646 Background: To investigate whether excision repair cross-complementation group 1 (ERCC1) expression, as determined immunohistochemically, and mutations of epidermal growth factor receptor (EGFR) are related to the prognosis of curatively resected non-small cell lung cancer (NSCLC), and whether these two markers are related. Methods: One-hundred and thirty-three consecutive patients with NSCLC who did not receive adjuvant chemotherapy after curative surgery were included in this study. Representative areas from formalin-fixed paraffin-embedded tumor samples were chosen for tissue microarray analysis. Immunohistochemistry was performed for ERCC1 and the median semiquantitative H-score was used as a cut-off. EGFR mutations (exons 18, 19, and 21) were analyzed by the direct sequencing of tumor samples. Results: ERCC1 expression was evaluable in 130 patients and ERCC1 was found to be positive in 80 patients (61.5%). Moreover, ERCC1 was expressed more frequently in smokers and in squamous cell carcinomas. Patients with positive ERCC1 expression survived longer (median overall survival 2,742 days for ERCC1-positive vs. 1,423 days for ERCC1-negative, P=.0463). EGFR mutations were found in 27 patients (20.3%) but they were not found to affect overall survival. Interestingly, EGFR mutations were more frequent in ERCC1-negative tumors (12.5% in ERCC1-positive vs. 30% in ERCC1-negative tumors, P=0.014). Conclusions: ERCC1 expression was identified as a prognostic marker of longer survival in resected NSCLCs. In addition, EGFR mutations were more frequently found in ERCC1-negative tumors, but were not found to affect survival in our patient group. No significant financial relationships to disclose.
SURGICAL CIRCUMCISION.
Authors: FERD. C. VALENTINE
Journal: JAMA (1901)

It would be a work of supererogation to recite here the indications for removal of the prepuce; your specialty has made them an every-day occurrence through the whole gamut, from those immensely elongated foreskins with adhesions, concretions of urinary salts and smega, to the barely enlarged fold which causes no perceptible local disturbance and yet provokes most serious reflex conditions. I believe that my experience does not differ from that of other genito-urinary specialists, who are often called in by pediatrists or general practitioners to operate, and afterward learn that the removal of an almost normal foreskin was followed by cessation of enuresis, infantile convulsions, or glycosuria that had resisted other treatment. How should circumcision be performed, and who should perform it? The preparation of the field of operation is naturally the same as that employed for any other surgical procedure, and the details and precision to be observed are
AUTHORS' REPLY
Authors: B G Gazzard, D E Smith
Journal: Thorax (1993)

Notification of tuberculosis: how many cases are never reported?Tower Hamlets is not the only London borough to report significant recent under- notification of tuberculosis (27%) (December 1992;47:1015-8).Hickman et alt reported 26% undernotification of non-HIV associated tuberculosis and 60% undemoti- fication of HIV related tuberculosis for the Riverside DHA for the period April 1990 to March 1991.Riverside have tightened procedures to reduce or prevent undemotification and hopefully Tower Hamlets have done so too.Correction of undernotifica- tion from these districts, and possibly others, may be contributing to the recent rise in tuberculosis notifications in England and Wales, particularly since 1989.The use of pathology and microbiology services to supplement notification has been reported.2An integrated and centralised tuberculosis service for a district would overcome many of these problems, but it is easier to implement in a DHA or Trust without multiple units.In the Blackburn, Hyndburn and Ribble Valley DHA, served by two acute hospitals of 400 and 550 beds, there is no undernotification because of our integrated system which has three key components:1.There is agreement that all cases of adult tuberculosis of whatever type are
Smallpox Revisited?
Authors: Michael J Selgelid
Journal: The American Journal of Bioethics (2003)

This article reviews the history of smallpox and ethical issues that arise with its threat as a biological weapon. Smallpox killed more people than any infectious disease in history--and perhaps three times more people in the 20th Century than were killed by all the wars of that period. Following a WHO-sponsored global vaccination campaign, smallpox was officially declared eradicated in 1980. It has since been revealed that the Soviet Union, until its fall in the early 1990s, manufactured tens of tons of smallpox for military purposes. A worry is that some of this may have fallen into the hands of "rogue" nations or terrorists. Current U.S. debate questions whether smallpox vaccine should therefore be made available to the American public, which--like the rest of the world--now lacks immunity. Because the vaccine is considerably dangerous, public dialogue cannot resolve this matter if evidence material to the likelihood of attack is classified (i.e. secret). I conclude by recommending numerous future areas for ethics research related to the weaponization of smallpox.
Abstract 13344: Beneficial Effects of Long-acting Nifedipine on Coronary Vasomotion Abnormalities After Drug-Eluting Stent Implantation -The NOVEL Study
Authors: Ryuji Tsuburaya, Jun Takahashi, Akihiro Nakamura, Eiji Nozaki, Masafumi Sugi, Yoshito Yamamoto, Tetsuya Hiramoto, Satoru Horiguchi, Kanichi Inoue, Toshikazu Goto, Atsushi Kato, Tsuyoshi Shinozaki, Hiroaki Shimokawa
Journal: Circulation (2015)

Introduction: It is widely known that drug-eluting stents (DES) induce coronary vasomotion abnormalities. We have previously demonstrated that chronic treatment with long-acting nifedipine, which exerts cardiovascular protective effects through inhibition of vascular inflammation, suppresses DES-induced abnormal coronary vasoconstriction in pigs. In order to test whether this is also the case in humans, we performed a prospective, randomized, multicenter trial, termed as the NOVEL Study. Methods and Results: We enrolled 146 patients with stable angina pectoris who underwent elective implantation of everolimus-eluting stents (EES) in the left coronary arteries. They were randomly assigned to receive either conventional treatments alone (aspirin, clopidogrel, renin-angiotensin system inhibitor and statin) or additionally long-acting nifedipine (10-60 mg/day) (n=73 each). After 8-10 months, 53 patients in the control and 57 in the nifedipine group were finally examined for coronary reactivity to intracoronary acetylcholine (ACh) by quantitative coronary angiography after 48-hour withdrawal of nifedipine. Baseline patient characteristics and procedural profiles were comparable between the two groups. Coronary vasoconstricting responses to ACh were significantly enhanced at the distal segment adjacent to EES as compared with non-stented vessel (P&lt;0.001) and were significantly inhibited in the nifedipine group (P&lt;0.01) (Figure). Furthermore, the inflammatory profiles, including serum levels of high-sensitivity CRP and adiponectin, were improved only in the nifedipine group (P&lt;0.05) (Figure). Conclusions: These results indicate that DES-induced coronary vasomotion abnormalities still remain an important clinical issue even with the second-generation of DES, for which long-acting nifedipine exerts beneficial effects associated with its anti-inflammatory effects.
Regulation of Phosphoinositide Phospholipases by Hormones, Neurotransmitters, and Other Agonists Linked to G Proteins
Authors: J. H Exton
Journal: The Annual Review of Pharmacology and Toxicology (1996)

Since the spread of tobacco from the Americas hundreds of years ago, tobacco cigarettes and, more recently, alternative tobacco products have become global products of nicotine addiction. Within the evolving alternative tobacco product space, electronic ...Read More
THE IRRITABLE BLADDER.
Journal: JAMA (1904)

As the science of medicine grows older the use of such general terms as "irritable bladder" becomes less and less common on account of the fact that the pathologic conditions underlying such symptoms become gradually known, and the use of the symptom as a disease name ceases. At first sight irritable bladder as a symptomcomplex seems to belong to the class of diseases which have disappeared in the manner above mentioned, but a recent study by Hirsch<sup>1</sup>shows that although in many instances this condition is merely a symptom of other diseases, there are cases in which it can not be explained in this way. According to Hirsch cases which are described under the head of irritable bladder should have as their predominating symptoms frequency of urination with clear urine and a bladder which appears normal to the cystoscope. Hirsch admits that the number of such cases has been
A comparative study of apoptosis proliferation in germinoma and glioblastoma
Authors: Masahiro Mizoguchi, Takanori Inamura, Tadahisa Shono, Kiyonobu Ikezaki, Satoshi Inoha, Shoichiro Ohgami, Masashi Fukui
Journal: Neuro-Oncology (2000)

Intracranial germinoma has a relatively good prognosis when treated with radiotherapy and chemotherapy, whereas glioblastoma has a poor prognosis irrespective of these treatments.Cell proliferation and cell death are opposing processes in tumor growth, with tumor progression re ecting the balance between proliferating and apoptotic cells.We investigated cell proliferation and cell death using MIB-1 staining and nick-end labeling in 13 germinomas in comparison with 11 glioblastomas.Expression of BAX and Bcl-2, which regulate apoptosis, were studied by immunohistochemistry.Although germinomas showed strong MIB-1 immunostaining similar to that seen in glioblastomas, germinomas included signi cantly more apoptotic cells.The ratio of apoptotic ratio to MIB-1 labeling index for germinomas was 72.9 ± 36.9 (mean ± SD), a higher, statistically signi cant ratio as compared with glioblastomas (14.5 ± 11.2; P < 0.01).Furthermore, germinomas showed greater expression of BAX than did glioblastomas, while the expression of Bcl-2 was weak in both tumor types.A comparison of these apoptotic-related proteins showed that immunoreactivity for BAX was relatively higher in germinomas than in glioblastomas (P < 0.01), corresponding well to numerous apoptotic cells identi ed in germinoma tissues.These ndings may account for the prognostic difference between germinoma and glioblastoma in the face of a similar proliferation potential according to MIB-1 immunostaining.The balance between cell proliferation and death should be considered when predicting outcomes in patients with intracranial tumors.
Book Listings
Journal: Annals of Internal Medicine (2002)

Book Listings15 October 2002Book ListingsSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-137-8-200210150-00039 SectionsAboutFull Text ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail CardiologyAlcohol and Heart DiseaseR Watson and AK Myers, eds. 261 pages. Philadelphia: Taylor & Francis; 2002. $80.00. ISBN 0415273471. Order phone 800-821-8312.Beta-Blockers in Heart FailureJ McMurray and MJ Kendall. 108 pages. Philadelphia: Taylor & Francis; 2002. $15.00. ISBN 1853179027. Order phone 800-821-8312.Blackwell's Primary Care Essentials: CardiologyJ Sutherland. 304 pages. Cambridge, MA: Blackwell Science; 2001. $40.00. ISBN 0632044756. Order phone 800-759-6102.Cardiac Arrythmias: Practical Notes on Interpretation and Treatment6th edition. DH Bennett. 340 pages. Boston: Arnold; 2002. $30.00. ISBN 0340807318. Order phone 800-759-6102.Cardiogenic Shock: Diagnosis and TreatmentD Hasdai, PB Berger, A Battler, and DR Holmes Jr, eds. ... Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 15 October 2002Volume 137, Issue 8Page: B1 ePublished: 15 October 2002 Issue Published: 15 October 2002 Copyright & PermissionsCopyright © 2002 by American College of Physicians. All Rights Reserved.Loading ...
A 67-Year-Old Man Who e-Mails His Physician—Correction
Authors: Steven Wartman, John Littlefield
Journal: JAMA (2005)

2004, and a reminder message was sent on April 5. Frequency distributions were computed for the 14 categorical response items.Results.Responses were obtained from 98 (78%) of the 126 schools surveyed.The responses to the first 12 questions are shown in the TABLE.Fifty-five percent of schools report that they have modified their curriculum as a result of the Step 2 CS.Fifty percent of schools require passing scores in clinical coursework before taking the Step 2 CS and 63% require a passing score on this examination prior to graduation.Seventy-two percent of schools are taking steps to assist students with fees for taking the Step 2 CS and 54% of the schools are providing a practice examination to assist students with preparation.Faculty support for the Step 2 CS is mixed (46% positive/very positive, 29% indifferent, and 22% negative).Comment.The addition of the Step 2 CS as a new licensure requirement has led to curricular and other modifications, including access to additional student financial aid in a majority of US medical schools.The governance of medical schools reflects the interplay of societal issues, scientific advances, faculty concerns, and regulatory requirements (eg, physician licensure and institutional accreditation).Achieving an appropriate balance among these components is a challenging task for individual schools.Making a change in one requirement appears to result in a broad investment of resources by medical schools.However, it is not clear how the educational value of this new intervention can be measured.We believe that there should be an overarching review of this complex web of interacting bodies that affects the education of our nation' s physicians.
Liver transplantation
Journal: JAMA (1983)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
John Stehlin: holistic oncology and a nude mouse
Authors: G. McBride
Journal: JAMA (1979)

In 1967, John S. Stehlin, Jr, MD, left the M. D. Anderson Hospital and Tumor Institute in Houston, where he had been on the fulltime surgical staff for ten years, and went out on his own. His dream was not only to treat patients with cancer more "creatively" but to have a research laboratory in which only human cancers would be studied. Constant feedback would occur between the laborary and the bedside. Fulfillment of that dream seemed far away for the 44-year-old surgical oncologist with only $6,700 in his pocket. Yet Stehlin, with a little help from colleagues, friends, and grateful former patients, seems to have made it come true. Today, the Stehlin Foundation for Cancer Research in Houston, with 25 researchers, has an annual budget of $1 million. There, Stehlin and his young partners, surgical oncologists Peter D. de Ipolyi, MD, and Pierre J. Greeff, MD, are in the
Systematic review of adverse events reporting in clinical trials leading to approval of targeted therapy and immunotherapy
Authors: A. Antonuzzo, P. Bossi, L. Botta, P. Bironzo, C. Sonetto, G. Musettini, A. Sbrana, V. Di Giannantonio, L. Locati, M. Di Maio
Journal: Annals of Oncology (2016)
Multicentric warfarin‐induced skin necrosis complicating heparin‐induced thrombocytopenia
Authors: Theodore E. Warkentin, William M. Sikov, David P. Lillicrap
Journal: American Journal of Hematology (1999)

Two patients developed catastrophic multicentric skin necrosis while receiving warfarin to treat venous thromboembolism complicated by immune-mediated heparin-induced thrombocytopenia (HIT). Patient 1 developed skin necrosis involving the breasts, thighs, and face, as well as venous limb gangrene and bilateral hemorrhagic necrosis of the adrenal glands, resulting in death. The second patient developed bilateral mammary necrosis necessitating mastectomies, as well as skin necrosis involving the thigh. Neither patient had an identifiable hypercoagulable syndrome, other than HIT. HIT may represent a risk factor for the development of multicentric warfarin-induced skin necrosis (WISN). Am. J. Hematol. 62:44–48, 1999. © 1999 Wiley-Liss, Inc.
Mental Health Congress To Be Historic Event
Journal: JAMA (1962)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Performace of US citizen candidates on the January 1974 ECFMG examination
Authors: A. C. McGuinness
Journal: JAMA (1974)

A total of 663 candidates who were citizens of the United States at time of entry into a medical school outside of the United States or Canada took the January 1974 ECFMG examination. Of these candidates, 237 (35.7%) passed the examination. This compares with a worldwide pass rate of 40.7% for all 18,765 candidates in that examination. It was found that candidates in the last two years of medical school were more successful than those who had already graduated, and that the highest pass rate was found among those taking the examination for the first time. Because of factors such as changes in the curricula of foreign schools, considerable shifts in student populations among the various schools were observed. (<i>JAMA</i>229:431-434, 1974)
Clinical evaluation of low-dose intradermally administered hepatitis B virus vaccine. A cost reduction strategy
Authors: R. R. Redfield
Journal: JAMA (1985)

High cost and limited availability of the current hepatitis B virus vaccine lead to underutilization. To address this problem, we performed a vaccine trial comparing the currently recommended regimen of 20 μg of hepatitis B surface antigen (HBsAg) intramuscularly on days 0, 30, and 180, with a more economical regimen of 2 μg of HBsAg intradermally on days 0, 30, and 180. This trial was performed in 50 seronegative health care workers to assess the immunogenicity and local reactogenicity of both vaccine regimens. We found no significant difference in seroconversion between the intradermal group (96%) and the intramuscular group (100%). Mean ratios of test sample value to mean negative control value for antibody to HBsAg at 360 days were not significantly different (intradermal group, 84 ±26; intramuscular group, 120 ±22). Reactions in both groups were minor. Although the optimal dose of HBsAg was not investigated, our data demonstrate that 0.1 mL of inactivated hepatitis B virus vaccine (Heptavax-B) intradermally is immunogenic in healthy adults. Vaccination by this regimen can broaden hepatitis B virus disease prevention. (<i>JAMA</i>1985;254:3203-3206)
Treatment of Scarlatinal Nephritis.
Journal: JAMA (2000)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Syphilitic Marriages.
Authors: Burnside Foster
Journal: JAMA (1894)

St. Paul, Minn., Sept. 20, 1894. <h3>To the Editor:</h3> —For the purpose of securing reliable statistics on the subject of the marriage of syphilitics, I desire to enlist the assistance of those of your readers who have had experience which will be of value in determining the period when this disease ceases to be communicable and inheritable. I shall, therefore, esteem it a great favor on the part of any physician who will send me answers to the following questions; and due credit will be given in a future publication to those who desire to aid me in this work: What is the latest period from the date of the initial lesion that you have known the disease to be communicated by a patient who has been from the first under your observation? What is the latest period from the date of the initial lesion that you have known:<i>a</i>, a syphilitic man, or<i>b</i>, a syphilitic woman to become the parent of a syphilitic child?